MENOPAUSE AND THE MENOPAUSAL TRANSITION

The menopause reference for clinicians who have to defend a decision, not just cite one.

Menopause is the only universal endocrinopathy. Every woman who lives past midlife will experience it, and roughly a third of the female lifespan is spent in the postmenopausal state. Yet most residency programmes teach almost none of it.

This is a working reference for the specialist. Across 41 chapters and more than 550 AMA-style references, it covers the biology, the evidence, and the prescribing in the depth a challenged decision requires.

WHAT MAKES IT DIFFERENT

Mechanism before management. Every therapeutic chapter is preceded by the physiology that makes the therapy rational.

Primary evidence, not guideline recitation. WHI, HERS, DOPS, ELITE, KEEPS, SWAN, SKYLIGHT and OASIS are examined at the level of design, population, endpoint and limitation.

The 2002 to 2025 arc, in full - including the November 2025 removal of the class boxed warning, and the arrival of fezolinetant and elinzanetant.

Risk in absolute numbers: events per 1,000 women over five years, by age, route and regimen.

Honest about its own gaps.

BUILT FOR USE

Learning objectives, key points and clinical pearls in every chapter; formulary tables for five jurisdictions; six clinical decision trees; six plain-language patient handouts free to photocopy; validated instruments with licensing status; counselling scripts; full index.

A reference work for qualified healthcare professionals.